Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bladder Cancer
Preclinical research programs at universities added to bladder cancer studies
June 6th, 2005
Senesco Technologies, Inc. (SNT) announced that it has added 2 preclinical human health research programs to further characterize the role of its proprietary technologies. The goal of these studies is to add more data to the company's body of work in the research of both cancer and inflammatory disease. The company will fund an in vitro bladder cancer study at the University of Virginia that will collect data by upregulating the company's Factor 5A gene in a human bladder cancer cell line. In this way, Senesco hopes to learn if its technology can kill bladder cancer cells. Bladder cancer affects approximately 60,000 new patients in the U.S. each...
Source: Biotech Business Week (2005-06-06)
|
